ReviewNature reviews. Neurology2009
Imaging outcomes for neuroprotection and repair in multiple sclerosis trials.
Review in Nature reviews. Neurology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 156 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
OxCarbazepine as a Neuroprotective Agent in MS: A Phase 2a Trial
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
Randomized, Controlled Pilot Trial of Domperidone in Relapsing-Remitting Multiple Sclerosis
An Open-label, Non-randomized, Phase I/II Study of Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and Liberation Therapy (When Associated With Chronic Cerebrovascular Venous Insufficiency) in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)
An Open-label, Non-randomized, Phase I/II Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
Who cites it
156 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Commercial volumetric MRI reporting tools in multiple sclerosis: a systematic review of the evidence.Neuroradiology · 2023Pooled it
- Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.Nature reviews. Neurology · 2015Guideline
- Reliability of Intra-Retinal Layer Thickness Estimates.PloS one · 2015Pooled it
- Pooled it
- Laquinimod for multiple sclerosis.The Cochrane database of systematic reviews · 2013Pooled it
- Quantitative neuroimaging measures of myelin in the healthy brain and in multiple sclerosis.Human brain mapping · 2019Trial
- Trial
- Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis.Contemporary clinical trials · 2016Trial
- Clinical Feasibility of Synthetic MRI in Multiple Sclerosis: A Diagnostic and Volumetric Validation Study.AJNR. American journal of neuroradiology · 2016Trial
- Sample-size calculations for short-term proof-of-concept studies of tissue protection and repair in multiple sclerosis lesions via conventional clinical imaging.Multiple sclerosis (Houndmills, Basingstoke, England) · 2015Trial
- Magnetization transfer ratio in the delayed-release dimethyl fumarate DEFINE study.Journal of neurology · 2014Trial
- Randomized placebo-controlled phase II trial of autologous mesenchymal stem cells in multiple sclerosis.PloS one · 2014Trial
- Trial
- The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.Journal of neuroimaging : official journal of the American Society of NeuroimagingTrial
- Article
- Translational molecular imaging and drug development in multiple sclerosis.Theranostics · 2026Review
- Corneal Confocal Microscopy Identifies and Differentiates Patients With Multiple Sclerosis and Epilepsy.Translational vision science & technology · 2024Article
- Glymphatic dysfunction in multiple sclerosis and its association with disease pathology and disability.Multiple sclerosis (Houndmills, Basingstoke, England) · 2024Article
- Effects of fingolimod on focal and diffuse damage in patients with relapsing-remitting multiple sclerosis - The "EVOLUTION" study.Journal of neurology · 2024Observational
- Don't be late! Postponing cognitive decline and preventing early unemployment in people with multiple sclerosis: a study protocol.BMC neurology · 2024Article
96 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is commonly regarded as an inflammatory disease, but it also has a neurodegenerative component, which represents an additional target for treatment. The use of MRI to evaluate the inflammatory disease component in 'proof-of concept' clinical trials is well established, but no systematic assessment of imaging outcomes to evaluate neuroprotection or repair in MS has been performed. In this Review, we examine the potential of traditional and novel imaging parameters to serve as primary outcomes in phase II clinical trials of neuroprotective and reparative strategies in MS. We present the conclusions of an international meeting of imaging, clinical and statistical experts, as well as a review of relevant literature. The available imaging techniques are appraised in five categories of performance: pathological specificity, reproducibility, sensitivity to change, clinical relevance, and response to treatment. At present, the three most promising primary outcomes in phase II trials of neuroprotective and/or reparative strategies in MS are: changes in whole-brain volume to gauge general cerebral atrophy; T1 hypointensity and magnetization transfer ratio to monitor the evolution of lesion damage; and optical coherence tomography findings to evaluate the anterior visual pathway. Power calculations show that these outcome measures can be applied with attainable sample sizes.
Indexed as
Identifiers
19488083What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.